Feeds:
Posts
Comments

Archive for the ‘BMS’ Category

Finally – FDA approves DSI/Lilly blood thinner Effient. Narrow indication with warnings, however – The approval makes Lilly‘s Effient the first real competition to the blood thinner Plavix, the world’s second-best selling medication made by Sanofi-Aventis and Bristol-Myers Squibbmore

Debate ignited over newer vs. older schizophrenia drugs – Schizophrenia patients given a cheap older drug are less likely to die prematurely than people on newer treatments, despite the older product’s well-known adverse side effects, Finnish researchers said on Mondaymore

Sermo and AMA get into a public spat. Who represents doctors, really?

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza.

Teva blocked from launching generic form of Lilly‘s Evista; also rumored to be eyeballing a purchase of Watson.

Roche/Genentech‘s Avastin misses the mark in colon cancer study.

PLUS – you want pharma growth? Sanofi says, Go East! (I know another big pharma also ramping up very rapidly in China…)

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

J&J cutting 900 positions, mostly in salesDiversified healthcare company Johnson & Johnson said on Thursday it was eliminating 900 positions from its Ortho-McNeil-Janssen Pharmaceutical unit in the latest downsizing move in the drug industry. The reductions occurred across Ortho-McNeil-Janssen, but the majority of the jobs impacted were from sales, spokeswoman Kara Russell said.

More big-name hospital systems limiting drug industry tiesJust a few days after Johns Hopkins announced a stricter conflict-of-interest policy for its doctors, some big-name Massachusetts hospitals are moving in a similar direction. Doctors at Partners HealthCare, a system that includes Harvard-affiliated Mass General and Brigham and Women’s hospitals as well as outpatient clinics, will be barred from accepting free meals from drug makers. They will also be prohibited from serving on drug-company “speakers’ bureaus,” where doctors are paid to give talks to other doctors.

BMS, Biogen CEOs – no rush to be acquired, thank you very much.

PLUS – Priming the Discussion: your input sought on an upcoming session on Pharma Social Media and Business Opportunities.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Will pharma sales reps be able to go after overtime pay? According to a CT court, the answer is yes – Without getting too technical, at the core of the ruling is the fact that Pharmaceutical Sale Representatives do not actually sell anything. In fact, federal and state law precludes them from making the very sales that would make them exempt. Rather, their role is to inform health care providers about the benefits of a given drug and to attempt to convince those professionals to write prescriptions.

Lying. Not recommended. Ask this BMS exec…oh, and while you’re at it – a cautionary tale about laptops in planes.

New drugs – Sanofi‘s Aplenzin for depression is approved; Watson‘s Rapaflo (approved for BPH in the fall) now available.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Teva‘s Copaxone approved for preventative treament of MS – The drug is already approved to treat relapsing-remitting multiple sclerosis, where new symptoms occur suddenly or older symptoms become worse. The expanded approval allows for the drug’s use in people who have experienced a first episode of multiple sclerosis and have magnetic resonance imaging results consistent with the condition.

Pfizer and Bausch & Lomb in co-promote agreement for eyecare productsPfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.

Vertex makes a strategic acquisition to boost pipeline. And, Bristol does some shuffling at the top.

PLUS – life after pharmaceutical sales. Dog washing. Endurance Sports. I’m betting that there are a lot more entrepreneurs among those downsized from pharma…

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Reblog this post [with Zemanta]

Read Full Post »

Sepracor cutting 20% of its workforce. Ouch. Sepracor Inc, maker of the Lunesta sleep drug, said on Wednesday it would cut about 20 percent of its workforce, or 530 jobs, in an effort to save some $210 million in expenses, and its shares jumped 17 percent. The company said most of the cuts would come from field-based positions, leaving it with a sales force of about 1,325 after the restructuring moves.

Zoloft and Lexapro still the ones? Pfizer Inc’s Zoloft and Forest Laboratories Inc’s  Lexapro are the most effective and well-tolerated antidepressants among a group of 12 new drugs, according to an analysis published on Thursday.

The physician sense of entitlement – what do you think? An interesting thought from Daniel Carlat‘s Psychiatry blog.

PLUS – speculation about Bristol being the next acquisition target. Blah, blah, blah…that talk has been around for years. Meanwhile, Novartis not looking at any big deals in the near term.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Join a Linkedin Pharma Professionals Networking Group.

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.

Reblog this post [with Zemanta]

Read Full Post »

Astellas makes a big to acquire CV Therapeutics. Japan’s Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday’s close.

Abilify as an add-on therapy for depression – not everyone is convinced.

Watson‘s topical Overactive Bladder gel (Gelnique) gets FDA approval.

PLUS – Amylin hurting. Abbott‘s Vicodin CR delay means 200 layoffs. And Feds say, “Enough with the off-label promotion already!

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.

Reblog this post [with Zemanta]

Read Full Post »

« Newer Posts - Older Posts »